Meanwhile, the BSE Sensex was up 95.21 points, or 0.33%, to 28,856.80.

On the BSE, so far 5.98 lakh shares were traded in the counter, compared with average daily volumes of 5.69 lakh shares in the past one quarter. The stock had hit a high of Rs 50.75 and a low of Rs 48.60 so far during the day.

The stock hit a 52-week high of Rs 58.30 on 4 October 2016. The stock hit a 52-week low of Rs 33.45 on 1 March 2016. The stock had outperformed the market over the past 30 days till 21 February 2017, rising 30.46% compared with the 6.06% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 20.55% as against Sensex's 10.40% rise.

The small-cap company has equity capital of Rs 40.93 crore. Face value per share is Re 1.

Shares of Marksans Pharma rose 34.62% in four trading sessions to settle at Rs 50.75 yesterday, 21 February 2017, from its close of Rs 37.70 on 15 February 2017.

The recent gains in the stock was triggered by the company's announcement that the UK MHRA completed the inspection of the company's facility without any critical observation.

Marksans Pharma announced during market hours on 20 February 2017, that its Goa plant's inspection by UK MHRA from 14th February 2017 to 17 February 2017 was completed without any critical observations. The stock had rallied 19.95% to settle at Rs 48.70 yesterday, 20 February 2017, post announcement.

Marksans Pharma's consolidated net profit fell 37% to Rs 11.30 crore on 1% decrease in net sales to Rs 215.24 in Q3 December 2016 over Q3 December 2015.

Marksans Pharma is a global pharmaceutical company. It is engaged in research & development (R&D) and offers CRAMS (contract research and manufacturing services) to global pharmaceutical companies.